siRNA Guarantee

(a) Silencer Select: Life Technologies guarantees that when you purchase two (2) Silencer Select pre-designed siRNA to the same target, then those two siRNAs will silence the target mRNA by 70% or more. To qualify for the guarantee, siRNAs must have been transfected at ≥5 nM and mRNA levels detected 48h post-transfection. Customers must also show ≥70%knockdown with a validated Silencer Select positive control siRNA in the same experiment to demonstrate transfection efficiency. We recommend the use of a Silencer Select non-targeting negative control to normalize mRNA knockdown. If the guaranteed level of knockdown is not observed while an appropriate positive control is successful, a new Silencer Select siRNA will be provided as a free-of-charge replacement. Requests for replacement product must be made within one hundred and eighty (180) days from the date of delivery of the Silencer Select pre-designed siRNAs. This guarantee does not extend to any replacement product nor to siRNAs designed to silence lncRNAs.

(b) Stealth: Life Technologies guarantees that when you purchase three (3) Stealth pre-designed RNAi reagents to the same target, at least two of those reagents will silence the target mRNA by 70% or more. To qualify for the guarantee, Stealth RNAi must have been transfected at ≥20 nM and mRNA levels detected 48h post-transfection. Customers must also show ≥70%knockdown with a Stealth positive control reagent in the same experiment to demonstrate transfection efficiency. We recommend the use of a Stealth negative control to normalize message knockdown. If the guaranteed level of knockdown is not observed while an appropriate positive control is successful, a new Stealth reagent will be provided as a free-of-charge replacement. Requests for replacement product must be made within one hundred and eighty (180) days from the date of delivery of the Stealth pre-designed reagents. This guarantee does not extend to any replacement product.

(c) Silencer: Life Technologies guarantees that when you purchase three (3) Silencer pre-designed siRNAs to the same target, at least two of the siRNAs will silence the target mRNA by 70% or more. To qualify for the guarantee, siRNAs must have been transfected at 100 nM and mRNA levels detected 48h post-transfection. Customers must also show ≥70% knockdown with a validated Silencer positive control siRNA in the same experiment to demonstrate transfection efficiency. We recommend the use of a Silencer non-targeting negative control to normalize mRNA knockdown. If the guaranteed level of knockdown is not observed while an appropriate positive control is successful, a new Silencer siRNA will be provided as a free-of-charge replacement. Requests for replacement product must be made within one hundred and eighty (180) days from the date of delivery of the Silencer pre-designed siRNAs. This guarantee does not extend to any replacement product.

• Calandria et al (2015) NPD1-mediated stereoselective regulation of BIRC3 expression through cREL is decisive for neural cell survival, Cell Death and Differentiation, published online Jan 30.
• Bhinder B, Shum D, Li M, Ibanez G, Vlassov AV, et al. (2014) Discovery of a Dicer-Independent, Cell-Type Dependent Alternate Targeting Sequence Generator: Implications in Gene Silencing & Pooled RNAi Screens, PLoS One 9:e100676.
• Vinod Udayar et al (2013) A Paired RNAi and RabGAP Overexpression Screen Identifies Rab11 as a Regulator of β-Amyloid Production, Cell Reports 5:1552–1563.
  
• Virginie Buggia-Prévot et al (2013) A Function for EHD Family Proteins in Unidirectional Retrograde Dendritic Transport of BACE1 and Alzheimer's Disease Aβ Productio, Cell Reports 5:1536–1551.
• Blattmann P¹, Schuberth C, Pepperkok R, Runz H.(2013) RNAi-based functional profiling of loci from blood lipid genome-wide association studies identifies genes with cholesterol-regulatory function, PLoS Genet 9:e1003338.
• Pau G, Walter T, Neumann B, Hériché JK, Ellenberg J, Huber W1 (2013) Dynamical modelling of phenotypes in a genome-wide RNAi live-cell imaging assay, BMC Bioinformatics 14:308.
• Almaça J1, Faria D, Sousa M, Uliyakina I, Conrad C, Sirianant L, Clarke LA, Martins JP, Santos M, Heriché JK, Huber W, Schreiber R, Pepperkok R,Kunzelmann K, Amaral MD. (2013) High-content siRNA screen reveals global ENaC regulators and potential cystic fibrosis therapy targets, Cell 154:1390–400.
• Szymborska A1, de Marco A, Daigle N, Cordes VC, Briggs JA, Ellenberg J. (2013) Nuclear pore scaffold structure analyzed by super-resolution microscopy and particle averaging, Science. 9;341(6146):655–8.
• Stadler C, Hjelmare M, Neumann B, Jonasson K, Pepperkok R, Uhlén M, Lundberg E (2012) Systematic validation of antibody binding and protein subcellular localization using siRNA and confocal microscopy, Journal of Proteomics 75:2236-2251.
• Casanova CM1, Sehr P, Putzker K, Hentze MW, Neumann B, Duncan KE, Thoma C. (2012) Automated high-throughput RNAi screening in human cells combined with reporter mRNA transfection to identify novel regulators of translation, PLoS One 7(9).
• Chrissie Y. Lee, Ronald L. Johnson, Jennifer Wichterman-Kouznetsova, Rajarshi Guha, Marc Ferrer, Pinar Tuzmen, Scott E. Martin, Wenge Zhu, Melvin L. DePamphilis (2012)Design and evaluation of genome-wide libraries for RNA interference screens, Genome Biology11:R61.